A randomized phase 2 study reports efficacy for tislelizumab combined with lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma, with strong objective response rates and continued follow-up needed for durability. The trial adds to the growing use of dual-checkpoint and VEGF-pathway combinations in genetically defined renal cancers. While the dataset size remains typical for a phase 2 program in a rare molecular subgroup, the results matter for clinicians because fh-deficient RCC often has limited standard options. The combination also mirrors a strategy used across other tumor types—pairing PD-1 blockade with angiogenesis inhibition—to boost response rates. Developers will likely focus next on durability, safety management, and biomarker work that can identify which patients benefit most from the regimen.